We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
- Authors
Pescovitz, M D
- Abstract
Rituximab, chimeric anti-human CD20, is approved for treatment of B-cell lymphoma in adults. It is being used experimentally in other various immune-related diseases such as immune thrombocytopenic purpura, systemic lupus erythematosus, myasthenia gravis and rheumatoid arthritis. In transplant recipients, it is used for treatment of post-transplant lymphoproliferative disease, to anecdotally reduce pre-formed anti-HLA and anti-ABO antibodies and for the prevention and treatment of acute rejection. This article primarily reviews the science behind rituximab: its history, pharmacokinetics and potential mechanism of action. A need for controlled clinical trials is clearly indicated before the widespread use of this drug in transplant.
- Publication
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2006, Vol 6, Issue 5 Pt 1, p859
- ISSN
1600-6135
- Publication type
Journal Article
- DOI
10.1111/j.1600-6143.2006.01288.x